NAD+ and Epitalon: measured outcomes
The interesting comparison runs across the measurements. Blood, muscle, sleep and survival tell different stories.
Outcomes and study settings
I’d rather compare specific outcomes than pick an overall winner. Muscle, walking and mortality make awkward neighbours: only the Epithalamin paper followed human survival, and it used a different preparation.
| Outcome | Preparation and setting | Finding |
|---|---|---|
| Muscle insulin sensitivity | Oral NMN; postmenopausal women with prediabetes | Improved after 10 weeks; body composition and HbA1c unchanged. |
| Walking distance | Oral NMN; healthy middle-aged adults | Improved compared with placebo, alongside blood NAD+ and quality-of-life scores. |
| Whole-blood NAD+ | Oral NR; healthy overweight adults | Rose dose-dependently during an 8-week trial; adverse events did not differ significantly from placebo. |
| Telomere length | Epitalon; normal human cells and breast-cancer cell lines | Lengthened, largely through different mechanisms, in cell culture. |
| Melatonin production | Epithalon; cultured rat pineal cells | Melatonin synthesis activity and medium melatonin increased. Human sleep was not measured. |
| Mortality | Epithalamin, alone or with thymalin; older people | Reduced mortality associated with treatment; observational study with no randomized assignment or placebo. |
Different meanings of improvement
The muscle trial makes the point particularly well: insulin sensitivity improved while body composition and HbA1c remained unchanged. A selective response can be scientifically useful. It asks a more focused question about what happened in muscle and why other measurements stayed put.
Telomere lengthening raises a different difficulty. The normal-cell and cancer-cell experiment found the same direction of change through largely different processes. “More” supplies a direction, while health requires a judgment about consequences.
I appreciate how selective the muscle response was. The neighbouring benefits each need their own support. The NAD+ trials and Epitalon experiments have enough detail to reward that restraint.
Human benefit and safety
NMN and NR have the stronger controlled human evidence in this collection, chiefly for raising blood NAD+ with some narrower functional findings. A review of the human evidence still judged clinical efficacy limited. Extra years of healthy life have yet to be established.
For Epitalon, the direct evidence here largely concerns cultured cells. The human mortality association concerns the different preparation Epithalamin. Pharmacy-prepared NAD+ injections lack drug approval, and Epitalon lacks human-treatment approval in major Western countries. Short tolerability findings, cell responses and observational associations leave lasting human safety unresolved.